Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-18Clinical Trial Update: Integrated Treatment for Adolescents With ADHD [NA]
Clinical trial update for integrated treatment of adolescents with ADHD and substance use disorders; study completed with results posted in …
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD [Phase 3]
Phase 3 clinical trial evaluating SPN-812 (viloxazine extended-release) in adults with ADHD has completed; results posted in 2022.
-
FDA approval · 2022-07-08FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Lannett Company, Inc.)
FDA approved Lannett's generic combination of four amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine…
-
FDA approval · 2022-07-05FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE — Original Application (Neolpharma, Inc.)
FDA approved an original application for a generic product containing dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine…
-
FDA approval · 2022-06-23FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Trigen Laboratories, LLC)
FDA approved methylphenidate hydrochloride from Trigen Laboratories, LLC under an Original Application. The product is indicated for attenti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-08FDA Approved: GUANFACINE HYDROCHLORIDE — Original Application (TWi Pharmaceuticals, Inc.)
FDA approved guanfacine hydrochloride as an Original Application (ANDA) submission by TWi Pharmaceuticals, Inc., establishing a generic vers…
-
FDA approval · 2022-06-01FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) from NextWave Pharmaceuticals. This action updates the product's l…
-
FDA approval · 2022-06-01FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) from NextWave Pharmaceuticals, authorizing changes to its labeling…
-
FDA approval · 2022-05-26FDA Approved: ATOMOXETINE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for atomoxetine by Dr. Reddy's Laboratories Limited, resulting in a new generic entry for ADHD treat…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: A Randomized Trial of Interventions for Teenage Drivers With Attention Deficit Hyperactivity Disorder (ADHD) [NA]
A completed randomized trial evaluating interventions for teenage drivers with ADHD; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Melatonin in ADHD and Sleep Problems [Phase 4]
Phase 4 clinical trial update on melatonin for Attention Deficit Hyperactivity Disorder and sleep disorders.
-
CLINICAL_TRIALS trial_result · 2022-05-02Clinical Trial Update: Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating intranasal inhalations of M2 macrophage soluble factors for developmental speech disorders in children; …
-
FDA approval · 2022-04-29FDA Approved: QELBREE — Supplemental Application (Supernus Pharmaceuticals, Inc)
FDA approved a supplemental application for Qelbree (viloxazine hydrochloride) from Supernus Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity [Phase 3]
Phase 3 trial assessing methylphenidate late formula to reduce cannabis use in young patients with cannabis-related issues and ADHD; the stu…
-
FDA approval · 2022-04-22FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride CD (Lannett), a generic methylphenidate product.
-
CLINICAL_TRIALS trial_result · 2022-04-21Clinical Trial Update: Lifestyle Enhancement for ADHD Program [NA]
Clinical trial update for a lifestyle enhancement program targeting ADHD; study status is completed with results posted.
-
FDA approval · 2022-03-22FDA Approved: XELSTRYM — Original Application (Noven Therapeutics, LLC)
FDA approved XELSTRYM (dextroamphetamine) under an Original New Drug Application by Noven Therapeutics, LLC.
-
CLINICAL_TRIALS trial_result · 2022-03-21Clinical Trial Update: Web Based Tools to Improve Medication Continuity in Adolescents With ADHD [NA]
Completed clinical trial evaluating web-based tools to improve medication continuity in adolescents with ADHD; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: Effect of Omega-3 Fatty Acid on Cortical Function in ADHD [Phase 3]
Phase 3 clinical trial investigating the effect of omega-3 fatty acids on cortical function in ADHD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-14Clinical Trial Update: A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]
Phase 2 clinical trial of TD-9855 in adults with ADHD has completed with results posted.
-
FDA approval · 2022-03-14FDA Approved: METHYLPHENIDATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved a generic methylphenidate product (Original Application) from Mylan Pharmaceuticals Inc., for conditions such as ADHD and narco…
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Impact of Combined Medication and Behavioral Treatment for ASD & ADHD [Phase 2]
Phase 2 clinical trial on combined medication and behavioral treatment for autism spectrum disorder and attention-deficit/hyperactivity diso…
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application from Prasco Laboratories for a fixed-dose combination product containing four amphetamine salts …
-
FDA approval · 2022-02-25FDA Approved: DEXEDRINE SPANSULE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Dexedrine Spansule (dextroamphetamine sulfate) by Amneal Pharmaceuticals LLC.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dextroamphetamine sulfate from Prasco Laboratories under ANDA 040776, marking an approved modifi…